Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer

ConclusionsSP and XP were both effective and well tolerated. SP might be suitable for the pathological differentiated subtype of AGC.Clinical Trial Registration: The HERBIS-2, HERBIS-4A, and XParTS II trials were registered with UMIN-CTR as UMIN000006105, UMIN000006755, and UMIN000006045, respectively.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research